TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

RALDESY

TRAZODONE HYDROCHLORIDE
Approved 2024-11-26
1
Indication
--
Phase 3 Trials
1
Years on Market

Details

Status
Prescription
First Approved
2024-11-26
Routes
ORAL
Dosage Forms
SOLUTION

Companies

Active Ingredient: TRAZODONE HYDROCHLORIDE

RALDESY Approval History

Loading approval history...

What RALDESY Treats

1 indications

RALDESY is approved for 1 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Major Depressive Disorder
Source: FDA Label

RALDESY Boxed Warning

SUICIDAL THOUGHTS and BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] . Trazodone is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 )] . WARNING: SUICIDAL THOUGHTS and BEHAVIORS See full prescribing infor...

Drugs Similar to RALDESY

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

APLENZIN
BUPROPION HYDROBROMIDE
1 shared
BAUSCH
Shared indications:
Major Depressive Disorder
AUVELITY
BUPROPION HYDROCHLORIDE
1 shared
AXSOME
Shared indications:
Major Depressive Disorder
CAPLYTA
LUMATEPERONE TOSYLATE
1 shared
INTRA-CELLULAR
Shared indications:
Major Depressive Disorder
CELEXA
CITALOPRAM HYDROBROMIDE
1 shared
AbbVie
Shared indications:
Major Depressive Disorder
CONTRAVE
BUPROPION HYDROCHLORIDE
1 shared
NALPROPION
Shared indications:
Major Depressive Disorder
DESVENLAFAXINE SUCCINATE
DESVENLAFAXINE SUCCINATE
1 shared
ALEMBIC
Shared indications:
Major Depressive Disorder
DRIZALMA SPRINKLE
DULOXETINE HYDROCHLORIDE
1 shared
Sun Pharma
Shared indications:
Major Depressive Disorder
EFFEXOR XR
VENLAFAXINE HYDROCHLORIDE
1 shared
UPJOHN
Shared indications:
Major Depressive Disorder
EMSAM
SELEGILINE
1 shared
SOMERSET
Shared indications:
Major Depressive Disorder
EXXUA
GEPIRONE HYDROCHLORIDE
1 shared
FABRE KRAMER
Shared indications:
Major Depressive Disorder
FETZIMA
LEVOMILNACIPRAN HYDROCHLORIDE
1 shared
AbbVie
Shared indications:
Major Depressive Disorder
FORFIVO XL
BUPROPION HYDROCHLORIDE
1 shared
TWI PHARMS
Shared indications:
Major Depressive Disorder
LEVOMILNACIPRAN HYDROCHLORIDE
LEVOMILNACIPRAN HYDROCHLORIDE
1 shared
PRINSTON INC
Shared indications:
Major Depressive Disorder
NEFAZODONE HYDROCHLORIDE
NEFAZODONE HYDROCHLORIDE
1 shared
Teva
Shared indications:
Major Depressive Disorder
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE
1 shared
Teva
Shared indications:
Major Depressive Disorder
OPIPZA
ARIPIPRAZOLE
1 shared
XIAMEN LP PHARM CO
Shared indications:
Major Depressive Disorder
PARNATE
TRANYLCYPROMINE SULFATE
1 shared
ADVANZ PHARMA
Shared indications:
Major Depressive Disorder
PAROXETINE
PAROXETINE HYDROCHLORIDE
1 shared
PRINSTON INC
Shared indications:
Major Depressive Disorder
PAXIL CR
PAROXETINE HYDROCHLORIDE
1 shared
Apotex
Shared indications:
Major Depressive Disorder
PRISTIQ
DESVENLAFAXINE SUCCINATE
1 shared
PF PRISM CV
Shared indications:
Major Depressive Disorder
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

RALDESY FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Trazodone is a selective serotonin reuptake inhibitor indicated for the treatment of major depressive disorder (MDD) . Trazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD) in adults.

โš ๏ธ BOXED WARNING

WARNING: SUICIDAL THOUGHTS and BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors...

RALDESY Patents & Exclusivity

Latest Patent: Mar 2029

Patents (1 active)

US8133893 Expires Mar 13, 2029
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.